Reuters -- Indian drugmaker Ranbaxy Laboratories Ltd said on Thursday its wholly-owned U.S.-based unit Ohm Laboratories Inc has received a warning letter from the U.S. Food and Drug Administration (FDA) relating to violations of good manufacturing practices.
